COVID-19: Keep up to date with the latest pharmaceutical and healthcare news as the pandemic evolves

Leading the fight

Oxfordshire has a unique life sciences ecosystem which has enabled it to mobilise rapidly and lead the international response to COVID-19, says Sebastian Johnson
A double-edged sword

Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the Long Term Plan while putting others in jeopardy
Chain reaction

As the NHS battles to suppress the coronavirus, communities across Britain have been adjusting to a new reality. Meanwhile, pharma has taken on the task of managing, sustaining and boosting its international supply chains. The industry is, so far, rising to the challenge, creating a new template and a revised plan for the future

News

View all

Bayer's finerenone hits targets in diabetes/kidney disease trial

The drug hit primary and secondary goals of the Phase III FIDELIO-DKD renal outcomes study

10th July 2020

Research journals commit to action on equality

Joint commitment led by the Royal Society of Chemistry, which has created a framework to reduce bias and discrimination that it is hoped 'will help reshape journals all over the world'

10th July 2020

US priority review for AZ' Brilinta/aspirin combination

Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke

10th July 2020

Charity warns of 'catastrophic' effect of COVID-19 on stroke research

UK’s leading stroke charity warns research faces long-term threat due to coronavirus pandemic

10th July 2020

NICE backing for Takeda's Adcetris for rare lymphoma

Standard of care in untreated systemic anaplastic large cell lymphoma (sALCL) has not changed in several decades

10th July 2020

Web Exclusives

View all

A strong foundation

The value of pre-existing collaboration in COVID-19 clinical trials

Patient Partnership Index: ‘We Can’t Do It Alone’

David Peacock, MSD UK’s managing director, shares his thoughts on why companies should enter the Patient Partnership Index

Battling the cytokine storm

A look at some of pharma's approaches to addressing the potentially deadly hyperinflammation seen in some patients with COVID-19

The need for digitalisation of pharma R&D

If COVID-19 has taught us anything, it’s that we need speed and accuracy now, and digitalisation could help

Magazine

View more from the latest edition

The collapse in non-COVID care

While the NHS has focused on fighting coronavirus, care for non-COVID patients has dropped sharply. Will those patients come back?

Closing the distance

Remote treatment calls for a collaborative approach

Leading the fight

Oxfordshire has a unique life sciences ecosystem which has enabled it to mobilise rapidly and lead the international response to COVID-19, says Sebastian Johnson

Safety first

Andrew Rut on why drug safety should be top of mind during COVID-19 development

A secure connection?

The doctor will see you (online) now, but so could the fraudsters

In greener shoes

Is pharma ready for the effects of the climate crisis on global health?

Amplifying the ask of patient communities

Ben Osborn, Pfizer’s UK country manager, shares his thoughts on why the Patient Partnership Index and the values it celebrates matter more now than ever before....